NASH-linked changes impact metformin pharmacokinetics

NASH-linked changes impact metformin pharmacokinetics

(HealthDay)—Nonalcoholic steatohepatitis (NASH)-associated changes in liver function affect kidney transporter expression and metformin pharmacokinetics, according to an experimental study published online May 27 in Diabetes Care.

John D. Clarke, Ph.D., from the University of Arizona in Tucson, and colleagues examined how NASH affects kidney transporter expression and pharmacokinetics. They administered a single oral dose of [14C] metformin to C57BL/6 (WT) mice and mice with diabetes (ob/ob). Mice were fed a methionine and choline deficient (MCD) diet or a control diet.

The researchers found that, compared with WT/Control mice, metformin plasma concentrations were slightly elevated in the WT/MCD and ob/Control groups, and 4.8-fold higher in ob/MCD mice. In both genotypes, the MCD diet significantly increased plasma half-life and mean residence time, and decreased oral clearance. These changes were attributable to ob/ob and MCD diet-specific reductions in the kidney mRNA expression of Oct2 and Mate1; Oct1 mRNA expression was reduced only in ob/MCD .

"These results indicate that the diabetic ob/ob genotype and the MCD disease model alter kidney transporter expression and alter the pharmacokinetics of metformin, potentially increasing the risk of drug toxicity," the authors write.

Explore further

Non-ob-gyns deliver about 14 percent of routine prenatal care

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2015 HealthDay. All rights reserved.

Citation: NASH-linked changes impact metformin pharmacokinetics (2015, June 4) retrieved 27 July 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments